Business
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the
About this update from Geovax Labs, Inc.
[{"type":"text","content":"Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate\nSignificant milestone achieved towards implementation of a commercially validated manufacturing system\nProgress across pipeline with planned data readouts for GEO-CM04S1 in multiple trials and Gedeptin(R) in healthy patient boost trial on track for later this year\nCompany to host conference call and webcast today at 4:30 p.m. ET\nATLANTA, GA - (NewMediaWire) - May 14, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.\nDavid Dodd, GeoVax's Chairman and CEO, stated, \"Throughout the first quarter of 2024, we made considerable progress across our pipeline of differentiated vaccines and immunotherapies. Our focus continued to be on the advancement of the ongoing clinical trials for our Gedeptin(R) cancer therapy targeting advanced head and neck cancers and GEO-CM04S1, our next-generation SARS-CoV-2 (COVID-19) vaccine. Positive initial safety and immune response findings from our Phase 2 clinical trial of GEO-CM04S1 were reported earlier in the year, and our Gedeptin Phase 1/2 clinical study in patients suffering from advanced head and neck cancer completed enrollment. Completion of this trial will be a significant milestone in the Gedeptin clinical development program. We look forward to reporting further progress on each of our ongoing clinical trials as well as our additional data readouts throughout the remainder of the year.\"\nDodd continued, \"In addition to our pipeline progress, the first quarter had other notable achievements for GeoVax. With our transition to implementing a commercial validated manufacturing, we released the first lot of GEO-CM04S1 produced with a commercial manufacturing platform, marking the successful completion of the transfer and scale-up of manufacturing to our experienced CDMO at ABL Europe. Additionally, we recently received multiple actions by global patent offices, further strengthening our intellectual property assets. This is an exciting time for us as we continue to successfully execute on our long-term strategy acros...